07.11.16
Headquarters: Petach Tivka, Israel
twitter.com/tevapharm
www.tevapharm.com
Headcount: 42,888
Year Established: 1901
Revenues: $19,652 (-3%)
Specialty Pharma Revenues: $8,338 (-3%)
Net Income: $1,597 (-48%)
R&D: $1,525 (+2%)
TOP SELLING DRUGS
Generic drug giant Teva reported sales of $19.7 billion in 2015. The company’s generics business generated 49% of total revenue and includes tablets, capsules, injectables, inhalants, liquids, ointments and creams. Teva is the leading generic drug company in the U.S. and Europe, with 51% of generic revenues in the United States, 28% in Europe and 21% in ROW markets.
Teva’s specialty medicines segment includes several franchises, most significantly in the therapeutic areas of central nervous system (CNS) medicines, such as Copaxone, Azilect, Nuvigil and Zecuity and respiratory medicines such as ProAir HFA and QVAR. The specialty medicines segment was responsible for 42% of total revenue and includes other therapeutic areas, such as oncology and women’s health.
The big news during the year came on the heals of a failed bid to buy Mylan. After the deal fell through Teva got back on the acquisition horse and acquired Allergan Generics for $40.5 billion, bringing together two leading generics businesses and catapulting Teva to the top of the generic leader board.
When combined, with Teva’s strong generics portfolio, Allergan Generics’ generics pipeline, which holds a leading position in first-to-file opportunities in the U.S., further enhances Teva’s stated goals of delivering the highest quality generic medicines at the most competitive prices and cultivating the best development pipeline in the industry. The resulting world-class product portfolio will be complemented by an expanded and more efficient global footprint, including leadership positions and strengthened operations, sales and R&D platforms in markets around the world.
The transaction has also bolstered Teva’s R&D capabilities in the generics industry, directed at fostering innovation, with approximately 320 combined pending ANDAs in the U.S., including exclusive offerings of approximately 110 U.S. FTF pending ANDAs.
During the year Teva also acquired Representacionese Investigaciones Médicas, S.A. de C.V. (Rimsa), a pharmaceutical manufacturing and distribution company in Mexico, along with a portfolio of products, assets, and companies in Latin America and Europe, for $2.3 billion. Rimsa had $227 million in revenues in 2014 with an annual growth of 11%. The company has an extensive portfolio of specialty products, including fixed-dose combination products. The deal makes Teva a leading pharma company in Mexico, the second largest market in Latin America.
Auspex Pharmaceuticals was also bought by Teva in a deal worth approximately $3.2 billion and expands Teva’s CNS franchise. Auspex’s lead investigational product, SD-809 (deutetrabenazine), leverages its deuterium technology platform, and is being developed for the potential treatment of chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. The company expects commercial launch for this indication in 2016.
The year also saw Teva divest several assets. ANI Pharmaceuticals acquired 22 previously marketed generic drug products from Teva for $25 million in cash and a percentage of future gross profits from product sales. The acquisition includes 19 solid-oral dosage products, and three oral suspension products. ANI will initially focus to tech transfer four products that qualify as CBE30 filings into ANI’s two manufacturing facilities; these four products have a combined trailing twelve month market value of $210 million, according to IMS Health. The total market value for the 22 products is $650 million on a trailing twelve-month basis, per IMS Health.
In other news, Ignyta, an oncology focused biopharma company, acquired worldwide rights and assets to four of Teva’s targeted oncology development programs for approximately $41.6 million.
Several alliances were formed during the year as well. Notably, Teva and Takeda established a new business venture to meet a range of needs for generics in Japan. Japan is among the fastest growing generics markets in the world, driven by social requirements for stable supply of affordable high quality medicines and the Japanese government’s policy of reduction of healthcare expenditures. Takeda’s strong distribution presence in Japan will combine with Teva’s supply chain, operational network, global commercial infrastructure, and R&D.
The business venture will offer patients and the healthcare system the portfolio of Teva’s generic medicines and Takeda’s products. Teva will have a 51% stake in the new company and Takeda will have 49%. The business venture will operate as an independent company with its own board of directors, chief executive officer, and executive leadership team.
In February 2015, Teva entered into an exclusive license agreement with Eagle Pharmaceuticals for Eagle’s EP-3102, a bendamustine hydrochloride rapid infusion product. In December 2015, the FDA approved the product, Bendeka (bendamustine hydrochloride), an injection for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Teva is responsible for all U.S. commercial activities for the product including promotion and distribution. Bendeka became commercially available in January 2016.
Teva also entered a partnership to explore ways to apply Microchips Biotech’s implantable drug delivery device to Teva’s portfolio of products to enhance clinical outcomes for chronic drug therapies. Microchips Biotech’s electronic device is made up of microchip arrays that can store hundreds of therapeutic doses of drug for periods ranging from months to years and releases each dose at precise times. The device can be programmed to release drug on a pre-determined schedule and will have wireless control features.
The partnership will initially focus on one selected disease area with the option to expand the program into several additional therapeutic areas. As programs advance, Microchips Biotech will receive development and commercial milestone payments and royalties on future product sales. Microchips will also receive funding to develop products for any future additional indications Teva may develop, and Teva will be responsible for Phase II and III development and regulatory filings.
Lastly, Teva entered an agreement to acquire Gecko Health Innovations, a software and product solutions company that aids in compliance and adherence improvement in the management of respiratory diseases. As a result of the deal, Teva gains CareTRx, a cloud-based solution designed to simplify chronic respiratory disease management, connecting patients and caregivers through remote monitoring and real-time adherence tools. Teva will explore ways to apply the CareTRx technology to its pipeline and portfolio of respiratory products with the goal of enhancing clinical outcomes.
twitter.com/tevapharm
www.tevapharm.com
Headcount: 42,888
Year Established: 1901
Revenues: $19,652 (-3%)
Specialty Pharma Revenues: $8,338 (-3%)
Net Income: $1,597 (-48%)
R&D: $1,525 (+2%)
TOP SELLING DRUGS
Drug | Indication | 2015 Sales | (+/-%) |
Copaxone | multiple sclerosis | $4,023 | -5% |
Treanda | cancer | $741 | -3% |
ProAir | asthma | $549 | 15% |
Azilect | Parkinson’s disease | $384 | -10% |
Nuvigil | insomnia | $373 - | -4% |
Qvar | asthma | $392 | 37% |
Generic drug giant Teva reported sales of $19.7 billion in 2015. The company’s generics business generated 49% of total revenue and includes tablets, capsules, injectables, inhalants, liquids, ointments and creams. Teva is the leading generic drug company in the U.S. and Europe, with 51% of generic revenues in the United States, 28% in Europe and 21% in ROW markets.
Teva’s specialty medicines segment includes several franchises, most significantly in the therapeutic areas of central nervous system (CNS) medicines, such as Copaxone, Azilect, Nuvigil and Zecuity and respiratory medicines such as ProAir HFA and QVAR. The specialty medicines segment was responsible for 42% of total revenue and includes other therapeutic areas, such as oncology and women’s health.
The big news during the year came on the heals of a failed bid to buy Mylan. After the deal fell through Teva got back on the acquisition horse and acquired Allergan Generics for $40.5 billion, bringing together two leading generics businesses and catapulting Teva to the top of the generic leader board.
When combined, with Teva’s strong generics portfolio, Allergan Generics’ generics pipeline, which holds a leading position in first-to-file opportunities in the U.S., further enhances Teva’s stated goals of delivering the highest quality generic medicines at the most competitive prices and cultivating the best development pipeline in the industry. The resulting world-class product portfolio will be complemented by an expanded and more efficient global footprint, including leadership positions and strengthened operations, sales and R&D platforms in markets around the world.
The transaction has also bolstered Teva’s R&D capabilities in the generics industry, directed at fostering innovation, with approximately 320 combined pending ANDAs in the U.S., including exclusive offerings of approximately 110 U.S. FTF pending ANDAs.
During the year Teva also acquired Representacionese Investigaciones Médicas, S.A. de C.V. (Rimsa), a pharmaceutical manufacturing and distribution company in Mexico, along with a portfolio of products, assets, and companies in Latin America and Europe, for $2.3 billion. Rimsa had $227 million in revenues in 2014 with an annual growth of 11%. The company has an extensive portfolio of specialty products, including fixed-dose combination products. The deal makes Teva a leading pharma company in Mexico, the second largest market in Latin America.
Auspex Pharmaceuticals was also bought by Teva in a deal worth approximately $3.2 billion and expands Teva’s CNS franchise. Auspex’s lead investigational product, SD-809 (deutetrabenazine), leverages its deuterium technology platform, and is being developed for the potential treatment of chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. The company expects commercial launch for this indication in 2016.
The year also saw Teva divest several assets. ANI Pharmaceuticals acquired 22 previously marketed generic drug products from Teva for $25 million in cash and a percentage of future gross profits from product sales. The acquisition includes 19 solid-oral dosage products, and three oral suspension products. ANI will initially focus to tech transfer four products that qualify as CBE30 filings into ANI’s two manufacturing facilities; these four products have a combined trailing twelve month market value of $210 million, according to IMS Health. The total market value for the 22 products is $650 million on a trailing twelve-month basis, per IMS Health.
In other news, Ignyta, an oncology focused biopharma company, acquired worldwide rights and assets to four of Teva’s targeted oncology development programs for approximately $41.6 million.
Several alliances were formed during the year as well. Notably, Teva and Takeda established a new business venture to meet a range of needs for generics in Japan. Japan is among the fastest growing generics markets in the world, driven by social requirements for stable supply of affordable high quality medicines and the Japanese government’s policy of reduction of healthcare expenditures. Takeda’s strong distribution presence in Japan will combine with Teva’s supply chain, operational network, global commercial infrastructure, and R&D.
The business venture will offer patients and the healthcare system the portfolio of Teva’s generic medicines and Takeda’s products. Teva will have a 51% stake in the new company and Takeda will have 49%. The business venture will operate as an independent company with its own board of directors, chief executive officer, and executive leadership team.
In February 2015, Teva entered into an exclusive license agreement with Eagle Pharmaceuticals for Eagle’s EP-3102, a bendamustine hydrochloride rapid infusion product. In December 2015, the FDA approved the product, Bendeka (bendamustine hydrochloride), an injection for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Teva is responsible for all U.S. commercial activities for the product including promotion and distribution. Bendeka became commercially available in January 2016.
Teva also entered a partnership to explore ways to apply Microchips Biotech’s implantable drug delivery device to Teva’s portfolio of products to enhance clinical outcomes for chronic drug therapies. Microchips Biotech’s electronic device is made up of microchip arrays that can store hundreds of therapeutic doses of drug for periods ranging from months to years and releases each dose at precise times. The device can be programmed to release drug on a pre-determined schedule and will have wireless control features.
The partnership will initially focus on one selected disease area with the option to expand the program into several additional therapeutic areas. As programs advance, Microchips Biotech will receive development and commercial milestone payments and royalties on future product sales. Microchips will also receive funding to develop products for any future additional indications Teva may develop, and Teva will be responsible for Phase II and III development and regulatory filings.
Lastly, Teva entered an agreement to acquire Gecko Health Innovations, a software and product solutions company that aids in compliance and adherence improvement in the management of respiratory diseases. As a result of the deal, Teva gains CareTRx, a cloud-based solution designed to simplify chronic respiratory disease management, connecting patients and caregivers through remote monitoring and real-time adherence tools. Teva will explore ways to apply the CareTRx technology to its pipeline and portfolio of respiratory products with the goal of enhancing clinical outcomes.